Nektar Therapeutics (NKTR)

6.87 -0.18  -2.55%  May 30, 8:00PM Go Pro
Watch this stock
View Full Chart NKTR Price Chart

Key Stats

Market Cap 787.39M
Revenue Growth 58.85%
Profit Margin -229.0%
Earnings Yield -17.75%
Dividend Yield 0.00%
Earnings Per Share TTM -1.22
PE Ratio
Price / Sales Ratio 10.08
52 Week High 9.71
52 Week Low 4.07
Beta 0.4662
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 30 Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 20...
May 25 watch list: $DEPO $ZLCS $CYTX $TSPT $HMA $HNSN $NKTR $THC by liwei90
May 24 New Ratings
May 24 Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) ...
May 24 Roth Capital Starts Nektar Therapeutics (NKTR) at Buy Street Insider
May 23 UPDATE: Jefferies Starts Nektar Therapeutics (NKTR) at Buy Street Insider
May 22 Jefferies Starts Dendreon (DNDN) at Underperform, Nektar (NKTR) at Buy Street Insider
May 09 Companies in the Pharmaceuticals Industry with the Best Relative Performance ($SLXP, $NKTR, $AKRX, $IPXL, $JNJ) -Financial News Network - by DrNick
May 04 NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report
May 03 Nektar Therapeutics Beats Up on Analysts Yet Again Fool
May 02 Listen to $NKTR Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3dPo by earningscast
Apr 30 $NKTR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aex by MarketBrief
Apr 23 RT @BenCBanks $WHR looks good too now, and so does $NKTR (if it beraks) by Mortiman

Profile

Exchange: NASDAQGS       Sector: Healthcare       Industry: Biotechnology

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, California.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Nektar Therapeutics is down 26.55% over the last year vs S&P 500 Total Return up 2.32%, Savient Pharmaceuticals down 90.74%, and Progenics Pharmaceuticals up 15.78%.

  • NKTR Total Returns
  • ^SPXTR Total Returns
  • SVNT Total Returns
  • PGNX Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring NKTR

Did Nektar Therapeutics make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

NKTR Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
NKTR 6.87 -0.18 -2.55% 807.44M
NKSH 29.00 -0.96 -3.20% 207.92M
NKO 14.93 +0.05 +0.32%
NKE 108.61 -2.31 -2.08% 50.84B
NKBP 4.50 -0.16 -3.43% 89.66M
NKA 11.67 -0.28 -2.34% 412.16M
NJR 41.80 -0.82 -1.92% 1.768B
NGSX 0.37 +0.00 +0.00% 11.07M
NGPC 6.71 +0.03 +0.45% 144.49M
NGLS 40.45 -0.92 -2.22% 3.764B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close